Metabolic profile in growth hormone-deficient (GHD) adults after long-term recombinant human growth hormone (rhGH) therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 1, 2013, Pages 352-361

  Claessen, Kim M J A ^a   Appelman Dijkstra, Natasha M ^a   Adoptie, Desirée M M M ^a   Roelfsema, Ferdinand ^a   Smit, Johannes W A ^a   Biermasz, Nienke R ^a   Pereira, Alberto M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN C; TRIACYLGLYCEROL;

ADULT; AGE; ANGINA PECTORIS; ANTHROPOMETRIC PARAMETERS; ARTICLE; BIOCHEMISTRY; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DRUG DOSE TITRATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HEART DEATH; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INCIDENCE; INTERMITTENT CLAUDICATION; LONG TERM CARE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; FEMALE; GROWTH DISORDERS; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; LONG-TERM CARE; MALE; METABOLOME; MIDDLE AGED; RECOMBINANT PROTEINS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872094426     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-2940     Document Type: Article

References (43)

1. Rosén T, Bengtsson BA 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 336:285-288
2. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM 2001 Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 357:425-431
3. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P 2004 Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab 89:2192-2199
4. Elbornsson M, Götherström G, Bosæus I, Bengtsson BÅ, Johannsson G, Svensson J 2012 Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 166:787-795
5. Götherström G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J 2007 Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol 156:55-64
6. Koltowska-Häggström M, Mattsson AF, Monson JP, Kind P, Badia X, Casanueva FF, Busschbach J, Koppeschaar HP, Johannsson G 2006 Does long-term GH replacement therapy in hypopituitary adults withGHdeficiency normalise quality of life? Eur J Endocrinol 155:109-119
7. Chrisoulidou A, Beshyah SA, Rutherford O, Spinks TJ, Mayet J, Kyd P, Anyaoku V, Haida A, Ariff B, Murphy M, Thomas E, Robinson S, Foale R, Johnston DG 2000 Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab 85:3762-3769
8. Götherström G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J 2007 A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab 92:1442-1445
9. van der Klaauw AA, Romijn JA, Biermasz NR, Smit JW, van Doorn J, Dekkers OM, Roelfsema F, Pereira AM 2006 Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. Eur J Endocrinol 155:701-708
10. van der Klaauw AA, Biermasz NR, Feskens EJ, Bos MB, Smit JW, Roelfsema F, Corssmit EP, Pijl H, Romijn JA, PereiraAM 2007 The prevalence of the metabolic syndrome is increased in patients with GH deficiency, irrespective of long-term substitution with recombinant human GH. Eur J Endocrinol 156:455-462
11. van Bunderen CC, van Nieuwpoort IC, Arwert LI, Heymans MW, Franken AA, Koppeschaar HP, van der Lely AJ, Drent ML 2011 Does growth hormone replacement therapy reduce mortality in adults with growth hormone deficiency? Data from the Dutch National Registry of Growth Hormone Treatment in Adults. J Clin Endocrinol Metab 96:3151-3159
12. Kokshoorn NE, Biermasz NR, Roelfsema F, Smit JW, Pereira AM, Romijn JA 2011 GH replacement therapy in elderly GH-deficient patients: a systematic review. Eur J Endocrinol 164:657-665
13. Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC, Lockhart S, Burnand KG, Salomon F, Sonksen PH, Russell-Jones D 1999 The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab 84:2596-2602
14. Roemmler J, Kuenkler M, Schneider HJ, Dieterle C, Schopohl J 2010 Comparison of glucose and lipid metabolism and bone mineralization in patients with growth hormone deficiency with and without long-term growth hormone replacement. Metabolism 59:350-358
15. Ghigo E, Aimaretti G, Corneli G 2008 Diagnosis of adult GH deficiency. Growth Horm IGF Res 18:1-16
16. Janssen YJ, Frölich M, Roelfsema F 1997 A low starting dose of genotropin in growth hormone-deficient adults. J Clin Endocrinol Metab 82:129-135
17. Janssen YJ, Hamdy NA, Frölich M, Roelfsema F 1998 Skeletal effects of two years of treatment with low physiological doses of recombinant human growth hormone (GH) in patients with adult-onset GH deficiency. J Clin Endocrinol Metab 83:2143-2148
18. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C 2004 Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109:433-438
19. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith Jr SC, Spertus JA, Costa F 2005 Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735-2752
20. Walker BR, Andrew R, MacLeod KM, Padfield PL 1998 Growth hormone replacement inhibits renal and hepatic 11 β-hydroxysteroid dehydrogenases in ACTH-deficient patients. Clin Endocrinol (Oxf) 49:257-263
21. Cole TJ 1990 The LMS method for constructing normalized growth standards. Eur J Clin Nutr 44:45-60
22. Rikken B, van Doorn J, Ringeling A, Van den Brande JL, Massa G, Wit JM 1998 Plasma levels of insulin-like growth factor (IGF)-I, IGF-II and IGF-binding protein-3 in the evaluation of childhood growth hormone deficiency. Horm Res 50:166-176
23. Verhelst J, Mattsson AF, Luger A, Thunander M, Goth MI, Koltowska-Haggstrom M, AbsR 2011 Prevalence and characteristics of the metabolic syndrome in 2479 hypopituitary patients with adult-onset GH deficiency before GH replacement: a KIMS analysis. Eur J Endocrinol 165:881-889
24. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD 1998 Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 97:946-952
25. Monson JP, Jönsson P, Koltowska-Häggström M, Kourides I 2007 Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. Clin Endocrinol (Oxf) 67:623-628
26. Schneider HJ, Klotsche J, Wittchen HU, Stalla GK, Schopohl J, Kann PH, Kreitschmann-Andermahr I, Wallaschofski H 2011 Effects of growth hormone replacement within the KIMS survey on estimated cardiovascular risk and predictors of risk reduction in patients with growth hormone deficiency. Clin Endocrinol (Oxf) 75:825-830
27. 2001 Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497
28. Attanasio AF, Mo D, Erfurth EM, Tan M, Ho KY, Kleinberg D, Zimmermann AG, Chanson P 2010 Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab 95:74-81
29. Oosterwerff MM, van Schoor NM, Lips P, Eekhoff EM 21 March 2012 Osteocalcin as a predictor of the metabolic syndrome in older persons: a population-based study. Clin Endocrinol (Oxf) doi: 10.1111/j.1365-2265.2012. 04391.x
30. Giavoli C, Porretti S, Ronchi CL, Cappiello V, Ferrante E, Orsi E, Arosio M, Beck-Peccoz P 2004 Long-term monitoring of insulin sensitivity in growth hormone-deficient adults on substitutive recombinant human growth hormone therapy. Metabolism 53:740-743
31. Götherström G, Svensson J, Koranyi J, Alpsten M, Bosaeus I, Bengtsson B, Johannsson G 2001 A prospective study of 5 years of GHreplacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 86:4657-4665
32. Coutinho M, Gerstein HC, Wang Y, Yusuf S 1999 The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233-240
33. Gerstein HC 1997 Dysglycemia, not just diabetes, is a continuous risk factor for cardiovascular disease. Evid Based Cardiovasc Med 1:87-88
34. Heikens J, Ubbink MC, van der Pal HP, Bakker PJ, Fliers E, Smilde TJ, Kastelein JJ, Trip MD 2000 Long term survivors of childhood brain cancer have an increased risk for cardiovascular disease. Cancer 88:2116-2121
35. van Waas M, Neggers SJ, Pieters R, van den Heuvel-Eibrink MM 2010 Components of the metabolic syndrome in 500 adult longterm survivors of childhood cancer. Ann Oncol 21:1121-1126
36. Abs R, Mattsson AF, Bengtsson BA, Feldt-Rasmussen U, Góth MI, Koltowska-Häggström M, Monson JP, Verhelst J, Wilton P 2005 Isolated growth hormone (GH) deficiency in adult patients: baseline clinical characteristics and responses to GH replacement in comparison with hypopituitary patients. A sub-analysis of the KIMS database. Growth Horm IGF Res 15:349-359
37. Burgers AM, Biermasz NR, Schoones JW, Pereira AM, Renehan AG, Zwahlen M, Egger M, Dekkers OM 2011 Meta-analysis and dose-response metaregression: circulating insulin-like growth factor I (IGF-I) and mortality. J Clin Endocrinol Metab 96:2912-2920
38. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, de Cabo R, Cohen P, Longo VD 2011 Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Sci Transl Med 3:70ra13
39. Barzilai N, Huffman DM, Muzumdar RH, Bartke A 2012 The critical role of metabolic pathways in aging. Diabetes 61:1315-1322
40. Russell SJ, Kahn CR 2007 Endocrine regulation of ageing. Nat Rev Mol Cell Biol 8:681-691
41. Tatar M, Bartke A, Antebi A 2003 The endocrine regulation of aging by insulin-like signals. Science 299:1346-1351
42. Danilowicz K, Bruno OD, Manavela M, Gomez RM, Barkan A 2008 Correction of cortisol overreplacement ameliorates morbidities in patients with hypopituitarism: a pilot study. Pituitary 11:279-285
43. Filipsson H, Johannsson G 2009 GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. Eur J Endocrinol 161(Suppl 1):S85-S95